Barten, Markus J. and Sax, Balazs and Schopka, Simon and Amarelli, Cristiano and Epailly, Eric and Natali, Benedetta and Teszak, Timea and Gokler, Johannes and Borchert, Kathrin and Theil, Julia and Ingram, Andy and Zuckermann, Andreas (2023) European multicenter study on the real-world use and clinical impact of extracorporeal photopheresis after heart transplantation. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 42 (8). pp. 1131-1139. ISSN 1053-2498, 1557-3117
Full text not available from this repository. (Request a copy)Abstract
BACKGROUND: Aim of this study was to describe the real-world use of extracorporeal photopheresis (ECP) and assess its impact on clinical outcomes in the modern era of heart transplantation. METHODS: Seven transplant centers from 5 European countries participated in this retrospective, observational, single-arm chart review study. All patients received ECP after heart transplantation in 2015 or later. Data were extracted from medical records between November 2020 and December 2021. RESULTS: Overall, 105 patients were enrolled and followed for an average of 2 years after initiation of ECP. Reasons to start ECP were acute cellular rejection (35.2%), rejection prevention (32.4%), mixed rejection (18.1%), and antibody-mediated rejection (14.3%). Rejection ISHLT grades improved from start to end of ECP treatment in 92% of patients treated with ECP for rejection. Of patients who started ECP to prevent rejection, 88% remained free from any rejection despite a reduction of calcineurin inhibitors. Overall survival was 95%, and no deaths were related to ECP. Safety events occurred in 18 patients, of which 13 experienced complications with venous access. CONCLUSIONS: This study, the largest European ECP study in heart transplantation, demonstrates that ECP can effectively be used to treat different rejection types and to prevent rejection in the modern era of immunosuppression. Patients with rejections who have received ECP have shown high response as measured by histological improvements in ISHLT classification. A high percentage of patients in the prevention group remained free from rejection despite reduction in immunosuppression, in particular calcineurin inhibitors. J Heart Lung Transplant 2023;42:1131-1139 & COPY; 2023 The Author(s). Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CARDIAC ALLOGRAFT-REJECTION; ANTIBODY-MEDIATED REJECTION; INTERNATIONAL SOCIETY; PHOTOCHEMOTHERAPY; PREVENTION; GUIDELINES; RECIPIENTS; DIAGNOSIS; EFFICACY; REGISTRY; heart transplantation; rejection; prevention; extracorporeal photopheresis; observational |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Abteilung für Thoraxchirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Jan 2024 13:01 |
| Last Modified: | 30 Jan 2024 13:01 |
| URI: | https://pred.uni-regensburg.de/id/eprint/60602 |
Actions (login required)
 |
View Item |
